ID   DSRAD_HUMAN             Reviewed;        1226 AA.
AC   P55265; B1AQQ9; B1AQR0; D3DV76; O15223; O43859; O43860; Q9BYM3;
AC   Q9BYM4;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 4.
DT   22-JUL-2015, entry version 170.
DE   RecName: Full=Double-stranded RNA-specific adenosine deaminase;
DE            Short=DRADA;
DE            EC=3.5.4.37;
DE   AltName: Full=136 kDa double-stranded RNA-binding protein;
DE            Short=p136;
DE   AltName: Full=Interferon-inducible protein 4;
DE            Short=IFI-4;
DE   AltName: Full=K88DSRBP;
GN   Name=ADAR; Synonyms=ADAR1, DSRAD, G1P1, IFI4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND
RP   VARIANT GLY-100.
RX   PubMed=7972084; DOI=10.1073/pnas.91.24.11457;
RA   Kim U., Wang Y., Sanford T., Zeng Y., Nishikura K.;
RT   "Molecular cloning of cDNA for double-stranded RNA adenosine
RT   deaminase, a candidate enzyme for nuclear RNA editing.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:11457-11461(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS GLY-100 AND
RP   ARG-384.
RC   TISSUE=Kidney;
RX   PubMed=7565688;
RA   Patterson J.B., Samuel C.E.;
RT   "Expression and regulation by interferon of a double-stranded-RNA-
RT   specific adenosine deaminase from human cells: evidence for two forms
RT   of the deaminase.";
RL   Mol. Cell. Biol. 15:5376-5388(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 2 AND 3), AND VARIANTS
RP   GLY-100 AND ARG-384.
RC   TISSUE=Placenta;
RX   PubMed=9020165; DOI=10.1074/jbc.272.7.4419;
RA   Liu Y., George C.X., Patterson J.B., Samuel C.E.;
RT   "Functionally distinct double-stranded RNA-binding domains associated
RT   with alternative splice site variants of the interferon-inducible
RT   double-stranded RNA-specific adenosine deaminase.";
RL   J. Biol. Chem. 272:4419-4428(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 5), AND VARIANTS GLY-100
RP   AND ARG-384.
RC   TISSUE=Cervix carcinoma;
RA   Deblandre G., Marinx O., Nols C., Defrance P., Berr P., Huez G.,
RA   Caput D.;
RT   "The gene coding for the interferon-inducible human dsRNA adenosine
RT   deaminase is transcribed into several messengers specifying different
RT   proteins.";
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND VARIANTS
RP   GLY-100 AND ARG-384.
RC   TISSUE=Amygdala, and Fetal kidney;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   GLY-100.
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   ALTERNATIVE PROMOTER USAGE, AND INDUCTION.
RX   PubMed=10200312; DOI=10.1073/pnas.96.8.4621;
RA   George C.X., Samuel C.E.;
RT   "Human RNA-specific adenosine deaminase ADAR1 transcripts possess
RT   alternative exon 1 structures that initiate from different promoters,
RT   one constitutively active and the other interferon inducible.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:4621-4626(1999).
RN   [10]
RP   HOMODIMERIZATION.
RX   PubMed=12618436; DOI=10.1074/jbc.M213127200;
RA   Cho D.-S.C., Yang W., Lee J.T., Shiekhattar R., Murray J.M.,
RA   Nishikura K.;
RT   "Requirement of dimerization for RNA editing activity of adenosine
RT   deaminases acting on RNA.";
RL   J. Biol. Chem. 278:17093-17102(2003).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12665561; DOI=10.1242/jcs.00371;
RA   Desterro J.M.P., Keegan L.P., Lafarga M., Berciano M.T., O'Connell M.,
RA   Carmo-Fonseca M.;
RT   "Dynamic association of RNA-editing enzymes with the nucleolus.";
RL   J. Cell Sci. 116:1805-1818(2003).
RN   [12]
RP   FUNCTION.
RX   PubMed=15556947; DOI=10.1074/jbc.M407876200;
RA   Yang W., Wang Q., Howell K.L., Lee J.T., Cho D.-S.C., Murray J.M.,
RA   Nishikura K.;
RT   "ADAR1 RNA deaminase limits short interfering RNA efficacy in
RT   mammalian cells.";
RL   J. Biol. Chem. 280:3946-3953(2005).
RN   [13]
RP   FUNCTION.
RX   PubMed=15858013; DOI=10.1128/JVI.79.10.6291-6298.2005;
RA   Taylor D.R., Puig M., Darnell M.E., Mihalik K., Feinstone S.M.;
RT   "New antiviral pathway that mediates hepatitis C virus replicon
RT   interferon sensitivity through ADAR1.";
RL   J. Virol. 79:6291-6298(2005).
RN   [14]
RP   SUMOYLATION AT LYS-418, AND MUTAGENESIS OF LYS-418.
RX   PubMed=16120648; DOI=10.1091/mbc.E05-06-0536;
RA   Desterro J.M.P., Keegan L.P., Jaffray E., Hay R.T., O'Connell M.A.,
RA   Carmo-Fonseca M.;
RT   "SUMO-1 modification alters ADAR1 editing activity.";
RL   Mol. Biol. Cell 16:5115-5126(2005).
RN   [15]
RP   INTERACTION WITH ILF2 AND ILF3.
RX   PubMed=16055709; DOI=10.1128/MCB.25.16.6956-6963.2005;
RA   Nie Y., Ding L., Kao P.N., Braun R., Yang J.-H.;
RT   "ADAR1 interacts with NF90 through double-stranded RNA and regulates
RT   NF90-mediated gene expression independently of RNA editing.";
RL   Mol. Cell. Biol. 25:6956-6963(2005).
RN   [16]
RP   FUNCTION.
RX   PubMed=16475990; DOI=10.1111/j.1365-2893.2005.00663.x;
RA   Hartwig D., Schuette C., Warnecke J., Dorn I., Hennig H., Kirchner H.,
RA   Schlenke P.;
RT   "The large form of ADAR 1 is responsible for enhanced hepatitis delta
RT   virus RNA editing in interferon-alpha-stimulated host cells.";
RL   J. Viral Hepat. 13:150-157(2006).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-808, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-808, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa
RT   cells and high confident phosphopeptide identification by cross-
RT   validation of MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH EIF2AK2.
RX   PubMed=17079286; DOI=10.1128/JVI.01527-06;
RA   Nie Y., Hammond G.L., Yang J.H.;
RT   "Double-stranded RNA deaminase ADAR1 increases host susceptibility to
RT   virus infection.";
RL   J. Virol. 81:917-923(2007).
RN   [20]
RP   ALTERNATIVE SPLICING, SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=18178553; DOI=10.1074/jbc.M708316200;
RA   Cenci C., Barzotti R., Galeano F., Corbelli S., Rota R., Massimi L.,
RA   Di Rocco C., O'Connell M.A., Gallo A.;
RT   "Down-regulation of RNA editing in pediatric astrocytomas: ADAR2
RT   editing activity inhibits cell migration and proliferation.";
RL   J. Biol. Chem. 283:7251-7260(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-808, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-601; SER-614; SER-823
RP   AND SER-825, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   INTERACTION WITH UPF1, AND SUBCELLULAR LOCATION.
RX   PubMed=18362360; DOI=10.1073/pnas.0710576105;
RA   Agranat L., Raitskin O., Sperling J., Sperling R.;
RT   "The editing enzyme ADAR1 and the mRNA surveillance protein hUpf1
RT   interact in the cell nucleus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:5028-5033(2008).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [25]
RP   FUNCTION.
RX   PubMed=19710021; DOI=10.1074/jbc.M109.045146;
RA   Toth A.M., Li Z., Cattaneo R., Samuel C.E.;
RT   "RNA-specific adenosine deaminase ADAR1 suppresses measles virus-
RT   induced apoptosis and activation of protein kinase PKR.";
RL   J. Biol. Chem. 284:29350-29356(2009).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH EIF2AK2.
RX   PubMed=19605474; DOI=10.1128/JVI.02457-08;
RA   Clerzius G., Gelinas J.F., Daher A., Bonnet M., Meurs E.F.,
RA   Gatignol A.;
RT   "ADAR1 interacts with PKR during human immunodeficiency virus
RT   infection of lymphocytes and contributes to viral replication.";
RL   J. Virol. 83:10119-10128(2009).
RN   [27]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH TNFO1 AND XPO1.
RX   PubMed=19124606; DOI=10.1128/MCB.01519-08;
RA   Fritz J., Strehblow A., Taschner A., Schopoff S., Pasierbek P.,
RA   Jantsch M.F.;
RT   "RNA-regulated interaction of transportin-1 and exportin-5 with the
RT   double-stranded RNA-binding domain regulates nucleocytoplasmic
RT   shuttling of ADAR1.";
RL   Mol. Cell. Biol. 29:1487-1497(2009).
RN   [28]
RP   FUNCTION.
RX   PubMed=19651874; DOI=10.1093/nar/gkp604;
RA   Doria M., Neri F., Gallo A., Farace M.G., Michienzi A.;
RT   "Editing of HIV-1 RNA by the double-stranded RNA deaminase ADAR1
RT   stimulates viral infection.";
RL   Nucleic Acids Res. 37:5848-5858(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-601 AND THR-808, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [30]
RP   REVIEW.
RX   PubMed=20192758; DOI=10.1146/annurev-biochem-060208-105251;
RA   Nishikura K.;
RT   "Functions and regulation of RNA editing by ADAR deaminases.";
RL   Annu. Rev. Biochem. 79:321-349(2010).
RN   [31]
RP   FUNCTION.
RX   PubMed=19908260; DOI=10.1002/ijc.25022;
RA   Galeano F., Leroy A., Rossetti C., Gromova I., Gautier P.,
RA   Keegan L.P., Massimi L., Di Rocco C., O'Connell M.A., Gallo A.;
RT   "Human BLCAP transcript: new editing events in normal and cancerous
RT   tissues.";
RL   Int. J. Cancer 127:127-137(2010).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-808 AND SER-825, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [34]
RP   REVIEW.
RX   PubMed=22022963; DOI=10.1134/S0006297911080050;
RA   Wang Q.;
RT   "RNA editing catalyzed by ADAR1 and its function in mammalian cells.";
RL   Biochemistry (Mosc.) 76:900-911(2011).
RN   [35]
RP   FUNCTION.
RX   PubMed=21289159; DOI=10.1099/vir.0.028043-0;
RA   Doria M., Tomaselli S., Neri F., Ciafre S.A., Farace M.G.,
RA   Michienzi A., Gallo A.;
RT   "ADAR2 editing enzyme is a novel human immunodeficiency virus-1
RT   proviral factor.";
RL   J. Gen. Virol. 92:1228-1232(2011).
RN   [36]
RP   REVIEW.
RX   PubMed=21182352; DOI=10.1089/jir.2010.0097;
RA   George C.X., Gan Z., Liu Y., Samuel C.E.;
RT   "Adenosine deaminases acting on RNA, RNA editing, and interferon
RT   action.";
RL   J. Interferon Cytokine Res. 31:99-117(2011).
RN   [37]
RP   REVIEW.
RX   PubMed=21490091; DOI=10.1128/JVI.00240-11;
RA   Gelinas J.F., Clerzius G., Shaw E., Gatignol A.;
RT   "Enhancement of replication of RNA viruses by ADAR1 via RNA editing
RT   and inhibition of RNA-activated protein kinase.";
RL   J. Virol. 85:8460-8466(2011).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-825, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [39]
RP   REVIEW.
RX   PubMed=21211811; DOI=10.1016/j.virol.2010.12.004;
RA   Samuel C.E.;
RT   "Adenosine deaminases acting on RNA (ADARs) are both antiviral and
RT   proviral.";
RL   Virology 411:180-193(2011).
RN   [40]
RP   REVIEW.
RX   PubMed=22988838; DOI=10.3109/10409238.2012.714350;
RA   Mallela A., Nishikura K.;
RT   "A-to-I editing of protein coding and noncoding RNAs.";
RL   Crit. Rev. Biochem. Mol. Biol. 47:493-501(2012).
RN   [41]
RP   REVIEW.
RX   PubMed=21769729; DOI=10.1007/82_2011_144;
RA   Goodman R.A., Macbeth M.R., Beal P.A.;
RT   "ADAR proteins: structure and catalytic mechanism.";
RL   Curr. Top. Microbiol. Immunol. 353:1-33(2012).
RN   [42]
RP   FUNCTION.
RX   PubMed=22278222; DOI=10.1128/JVI.06307-11;
RA   Li Z., Okonski K.M., Samuel C.E.;
RT   "Adenosine deaminase acting on RNA 1 (ADAR1) suppresses the induction
RT   of interferon by measles virus.";
RL   J. Virol. 86:3787-3794(2012).
RN   [43]
RP   REVIEW.
RX   PubMed=22113393; DOI=10.1007/s12035-011-8220-2;
RA   Orlandi C., Barbon A., Barlati S.;
RT   "Activity regulation of adenosine deaminases acting on RNA (ADARs).";
RL   Mol. Neurobiol. 45:61-75(2012).
RN   [44]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 133-209 IN COMPLEX WITH
RP   Z-DNA.
RX   PubMed=10364558; DOI=10.1126/science.284.5421.1841;
RA   Schwartz T., Rould M.A., Lowenhaupt K., Herbert A., Rich A.;
RT   "Crystal structure of the Z alpha domain of the human editing enzyme
RT   ADAR1 bound to left-handed Z-DNA.";
RL   Science 284:1841-1845(1999).
RN   [46]
RP   STRUCTURE BY NMR OF 125-201 IN COMPLEX WITH Z-DNA AND ALONE.
RX   PubMed=10535945; DOI=10.1073/pnas.96.22.12465;
RA   Schade M., Turner C.J., Kuehne R., Schmieder P., Lowenhaupt K.,
RA   Herbert A., Rich A., Oschkinat H.;
RT   "The solution structure of the Zalpha domain of the human RNA editing
RT   enzyme ADAR1 reveals a prepositioned binding surface for Z-DNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:12465-12470(1999).
RN   [47]
RP   VARIANTS DSH PRO-923 AND SER-1165.
RX   PubMed=12916015; DOI=10.1086/378209;
RA   Miyamura Y., Suzuki T., Kono M., Inagaki K., Ito S., Suzuki N.,
RA   Tomita Y.;
RT   "Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are
RT   involved in dyschromatosis symmetrica hereditaria.";
RL   Am. J. Hum. Genet. 73:693-699(2003).
RN   [48]
RP   VARIANT DSH PHE-966.
RX   PubMed=15146470; DOI=10.1002/humu.9246;
RA   Zhang X.-J., He P.-P., Li M., He C.-D., Yan K.-L., Cui Y., Yang S.,
RA   Zhang K.-Y., Gao M., Chen J.-J., Li C.-R., Jin L., Chen H.-D.,
RA   Xu S.-J., Huang W.;
RT   "Seven novel mutations of the ADAR gene in Chinese families and
RT   sporadic patients with dyschromatosis symmetrica hereditaria (DSH).";
RL   Hum. Mutat. 23:629-630(2004).
RN   [49]
RP   VARIANT DSH TRP-1155.
RX   PubMed=15659327; DOI=10.1016/j.jdermsci.2004.11.004;
RA   Li C.-R., Li M., Ma H.-J., Luo D., Yang L.-J., Wang D.-G., Zhu X.-H.,
RA   Yue X.-Z., Chen W.-Q., Zhu W.-Y.;
RT   "A new arginine substitution mutation of DSRAD gene in a Chinese
RT   family with dyschromatosis symmetrica hereditaria.";
RL   J. Dermatol. Sci. 37:95-99(2005).
RN   [50]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-806.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [51]
RP   VARIANTS AGS6 ALA-193; THR-870; THR-872; HIS-892; ASN-999; ARG-1007;
RP   PHE-1112 AND HIS-1113.
RX   PubMed=23001123; DOI=10.1038/ng.2414;
RA   Rice G.I., Kasher P.R., Forte G.M., Mannion N.M., Greenwood S.M.,
RA   Szynkiewicz M., Dickerson J.E., Bhaskar S.S., Zampini M., Briggs T.A.,
RA   Jenkinson E.M., Bacino C.A., Battini R., Bertini E., Brogan P.A.,
RA   Brueton L.A., Carpanelli M., De Laet C., de Lonlay P., del Toro M.,
RA   Desguerre I., Fazzi E., Garcia-Cazorla A., Heiberg A., Kawaguchi M.,
RA   Kumar R., Lin J.P., Lourenco C.M., Male A.M., Marques W. Jr.,
RA   Mignot C., Olivieri I., Orcesi S., Prabhakar P., Rasmussen M.,
RA   Robinson R.A., Rozenberg F., Schmidt J.L., Steindl K., Tan T.Y.,
RA   van der Merwe W.G., Vanderver A., Vassallo G., Wakeling E.L.,
RA   Wassmer E., Whittaker E., Livingston J.H., Lebon P., Suzuki T.,
RA   McLaughlin P.J., Keegan L.P., O'Connell M.A., Lovell S.C., Crow Y.J.;
RT   "Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a
RT   type I interferon signature.";
RL   Nat. Genet. 44:1243-1248(2012).
CC   -!- FUNCTION: Catalyzes the hydrolytic deamination of adenosine to
CC       inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA
CC       editing. This may affect gene expression and function in a number
CC       of ways that include mRNA translation by changing codons and hence
CC       the amino acid sequence of proteins; pre-mRNA splicing by altering
CC       splice site recognition sequences; RNA stability by changing
CC       sequences involved in nuclease recognition; genetic stability in
CC       the case of RNA virus genomes by changing sequences during viral
CC       RNA replication; and RNA structure-dependent activities such as
CC       microRNA production or targeting or protein-RNA interactions. Can
CC       edit both viral and cellular RNAs and can edit RNAs at multiple
CC       sites (hyper-editing) or at specific sites (site-specific
CC       editing). Its cellular RNA substrates include: bladder cancer-
CC       associated protein (BLCAP), neurotransmitter receptors for
CC       glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor
CC       (GABRA3). Site-specific RNA editing of transcripts encoding these
CC       proteins results in amino acid substitutions which consequently
CC       alters their functional activities. Exhibits low-level editing at
CC       the GRIA2 Q/R site, but edits efficiently at the R/G site and
CC       HOTSPOT1. Its viral RNA substrates include: hepatitis C virus
CC       (HCV), vesicular stomatitis virus (VSV), measles virus (MV),
CC       hepatitis delta virus (HDV), and human immunodeficiency virus type
CC       1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or
CC       an antiviral effect (HCV) and this can be editing-dependent (HDV
CC       and HCV), editing-independent (VSV and MV) or both (HIV-1).
CC       Impairs HCV replication via RNA editing at multiple sites.
CC       Enhances the replication of MV, VSV and HIV-1 through an editing-
CC       independent mechanism via suppression of EIF2AK2/PKR activation
CC       and function. Stimulates both the release and infectivity of HIV-1
CC       viral particles by an editing-dependent mechanism where it
CC       associates with viral RNAs and edits adenosines in the 5'UTR and
CC       the Rev and Tat coding sequence. Can enhance viral replication of
CC       HDV via A-to-I editing at a site designated as amber/W, thereby
CC       changing an UAG amber stop codon to an UIG tryptophan (W) codon
CC       that permits synthesis of the large delta antigen (L-HDAg) which
CC       has a key role in the assembly of viral particles. However, high
CC       levels of ADAR1 inhibit HDV replication.
CC       {ECO:0000269|PubMed:15556947, ECO:0000269|PubMed:15858013,
CC       ECO:0000269|PubMed:16475990, ECO:0000269|PubMed:17079286,
CC       ECO:0000269|PubMed:19605474, ECO:0000269|PubMed:19651874,
CC       ECO:0000269|PubMed:19710021, ECO:0000269|PubMed:19908260,
CC       ECO:0000269|PubMed:21289159, ECO:0000269|PubMed:22278222}.
CC   -!- CATALYTIC ACTIVITY: Adenine in double-stranded RNA + H(2)O =
CC       hypoxanthine in double-stranded RNA + NH(3).
CC   -!- SUBUNIT: Homodimer. Homodimerization is essential for its
CC       catalytic activity. Isoform 5 can form heterodimers with
CC       ADARB1/ADAR2. Isoform 1 interacts with ILF2/NF45 and ILF3/NF90.
CC       Binding to ILF3/NF90 up-regulates ILF3-mediated gene expression.
CC       Isoform 5 (via DRBM 3 domain) interacts with TNPO1. Isoform 5 (via
CC       DRBM domains) interacts with XPO5. Isoform 1 and isoform 5 can
CC       interact with EIF2AK2/PKR and UPF1. {ECO:0000269|PubMed:10364558,
CC       ECO:0000269|PubMed:10535945, ECO:0000269|PubMed:16055709,
CC       ECO:0000269|PubMed:17079286, ECO:0000269|PubMed:18178553,
CC       ECO:0000269|PubMed:18362360, ECO:0000269|PubMed:19124606,
CC       ECO:0000269|PubMed:19605474}.
CC   -!- INTERACTION:
CC       Q99IB8:- (xeno); NbExp=3; IntAct=EBI-2462104, EBI-6858501;
CC       Q9UPY3:DICER1; NbExp=8; IntAct=EBI-6913210, EBI-395506;
CC       Q15633:TARBP2; NbExp=3; IntAct=EBI-6913210, EBI-978581;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Nucleus. Note=Shuttles
CC       between the cytoplasm and nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Cytoplasm. Nucleus. Nucleus,
CC       nucleolus. Note=Predominantly nuclear but can shuttle between
CC       nucleus and cytoplasm. TNPO1 can mediate its nuclear import
CC       whereas XPO1 can mediate its nuclear export.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=ADAR-a, ADAR1L, p150;
CC         IsoId=P55265-1; Sequence=Displayed;
CC         Note=Produced by alternative promoter usage.;
CC       Name=2; Synonyms=ADAR-b;
CC         IsoId=P55265-2; Sequence=VSP_008874;
CC         Note=Produced by alternative splicing of isoform 1.;
CC       Name=3; Synonyms=ADAR-c;
CC         IsoId=P55265-3; Sequence=VSP_008873, VSP_008874;
CC         Note=Produced by alternative splicing of isoform 1.;
CC       Name=4;
CC         IsoId=P55265-4; Sequence=VSP_008872;
CC         Note=Produced by alternative splicing of isoform 1. No
CC         experimental confirmation available. The N-terminus has been
CC         derived from EST and genomic sequences. Ref.5 (CAE45853)
CC         sequence is in conflict in position: 13:R->G. {ECO:0000305};
CC       Name=5; Synonyms=ADAR1S, p110;
CC         IsoId=P55265-5; Sequence=VSP_019235;
CC         Note=Produced by alternative promoter usage.;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, highest levels were
CC       found in brain and lung. Isoform 5 is expressed at higher levels
CC       in astrocytomas as compared to normal brain tissue and expression
CC       increases strikingly with the severity of the tumor, being higher
CC       in the most aggressive tumors. {ECO:0000269|PubMed:18178553}.
CC   -!- INDUCTION: Isoform 1 is induced by interferon alpha. Isoform 5 is
CC       constitutively expressed. {ECO:0000269|PubMed:10200312}.
CC   -!- PTM: Sumoylation reduces RNA-editing activity.
CC       {ECO:0000269|PubMed:16120648}.
CC   -!- DISEASE: Dyschromatosis symmetrica hereditaria (DSH) [MIM:127400]:
CC       An autosomal dominant pigmentary genodermatosis characterized by a
CC       mixture of hyperpigmented and hypopigmented macules distributed on
CC       the face and the dorsal parts of the hands and feet, that appear
CC       in infancy or early childhood. {ECO:0000269|PubMed:12916015,
CC       ECO:0000269|PubMed:15146470, ECO:0000269|PubMed:15659327}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Aicardi-Goutieres syndrome 6 (AGS6) [MIM:615010]: A form
CC       of Aicardi-Goutieres syndrome, a genetically heterogeneous disease
CC       characterized by cerebral atrophy, leukoencephalopathy,
CC       intracranial calcifications, chronic cerebrospinal fluid (CSF)
CC       lymphocytosis, increased CSF alpha-interferon, and negative
CC       serologic investigations for common prenatal infection. Clinical
CC       features as thrombocytopenia, hepatosplenomegaly and elevated
CC       hepatic transaminases along with intermittent fever may
CC       erroneously suggest an infective process. Severe neurological
CC       dysfunctions manifest in infancy as progressive microcephaly,
CC       spasticity, dystonic posturing and profound psychomotor
CC       retardation. Death often occurs in early childhood.
CC       {ECO:0000269|PubMed:23001123}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 1 A to I editase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00240}.
CC   -!- SIMILARITY: Contains 2 DRADA repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00073}.
CC   -!- SIMILARITY: Contains 3 DRBM (double-stranded RNA-binding) domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00266}.
CC   -!- CAUTION: The N-terminus of isoform 4 has been derived from EST and
CC       genomic sequences. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAE45853.1; Type=Erroneous termination; Positions=1227; Note=Translated as stop.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U10439; AAB06697.1; -; mRNA.
DR   EMBL; U75503; AAB97116.1; -; Genomic_DNA.
DR   EMBL; U75489; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75490; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75491; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75492; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75493; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75494; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75495; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75496; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75497; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75498; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75499; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75500; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75501; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75502; AAB97116.1; JOINED; Genomic_DNA.
DR   EMBL; U75503; AAB97117.1; -; Genomic_DNA.
DR   EMBL; U75489; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75490; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75491; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75492; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75493; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75494; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75495; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75496; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75497; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75498; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75499; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75500; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75501; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75502; AAB97117.1; JOINED; Genomic_DNA.
DR   EMBL; U75503; AAB97118.1; -; Genomic_DNA.
DR   EMBL; U75489; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75490; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75491; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75492; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75493; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75494; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75495; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75496; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75497; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75498; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75499; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75500; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75501; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U75502; AAB97118.1; JOINED; Genomic_DNA.
DR   EMBL; U18121; AAC13782.1; -; mRNA.
DR   EMBL; X79448; CAA55967.1; -; mRNA.
DR   EMBL; X79449; CAA55968.1; -; mRNA.
DR   EMBL; X98559; CAA67169.1; -; mRNA.
DR   EMBL; X98559; CAA67170.1; -; mRNA.
DR   EMBL; BX538232; CAD98075.1; -; mRNA.
DR   EMBL; BX640741; CAE45853.1; ALT_SEQ; mRNA.
DR   EMBL; AL606500; CAH71907.1; -; Genomic_DNA.
DR   EMBL; AL592078; CAH71907.1; JOINED; Genomic_DNA.
DR   EMBL; AL691488; CAH71907.1; JOINED; Genomic_DNA.
DR   EMBL; AL606500; CAH71908.1; -; Genomic_DNA.
DR   EMBL; AL592078; CAH71908.1; JOINED; Genomic_DNA.
DR   EMBL; AL691488; CAH71908.1; JOINED; Genomic_DNA.
DR   EMBL; AL592078; CAI16183.1; -; Genomic_DNA.
DR   EMBL; AL606500; CAI16183.1; JOINED; Genomic_DNA.
DR   EMBL; AL691488; CAI16183.1; JOINED; Genomic_DNA.
DR   EMBL; AL592078; CAI16185.1; -; Genomic_DNA.
DR   EMBL; AL606500; CAI16185.1; JOINED; Genomic_DNA.
DR   EMBL; AL691488; CAI16185.1; JOINED; Genomic_DNA.
DR   EMBL; AL691488; CAI17375.1; -; Genomic_DNA.
DR   EMBL; AL592078; CAI17375.1; JOINED; Genomic_DNA.
DR   EMBL; AL606500; CAI17375.1; JOINED; Genomic_DNA.
DR   EMBL; AL691488; CAI17376.1; -; Genomic_DNA.
DR   EMBL; AL592078; CAI17376.1; JOINED; Genomic_DNA.
DR   EMBL; AL606500; CAI17376.1; JOINED; Genomic_DNA.
DR   EMBL; CH471121; EAW53183.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53187.1; -; Genomic_DNA.
DR   EMBL; BC038227; AAH38227.1; -; mRNA.
DR   CCDS; CCDS1071.1; -. [P55265-1]
DR   CCDS; CCDS30879.1; -. [P55265-5]
DR   PIR; S65593; S65593.
DR   RefSeq; NP_001020278.1; NM_001025107.2. [P55265-5]
DR   RefSeq; NP_001102.2; NM_001111.4.
DR   RefSeq; NP_001180424.1; NM_001193495.1. [P55265-5]
DR   RefSeq; NP_056655.2; NM_015840.3.
DR   RefSeq; NP_056656.2; NM_015841.3.
DR   RefSeq; XP_006711174.1; XM_006711111.2. [P55265-5]
DR   RefSeq; XP_006711175.1; XM_006711112.1. [P55265-5]
DR   RefSeq; XP_006711176.1; XM_006711113.1. [P55265-5]
DR   UniGene; Hs.12341; -.
DR   PDB; 1QBJ; X-ray; 2.10 A; A/B/C=133-209.
DR   PDB; 1QGP; NMR; -; A=125-200.
DR   PDB; 1XMK; X-ray; 0.97 A; A=294-366.
DR   PDB; 2ACJ; X-ray; 2.60 A; A/B/C/D=140-202.
DR   PDB; 2GXB; X-ray; 2.25 A; A/B=140-202.
DR   PDB; 2L54; NMR; -; A=136-198.
DR   PDB; 2MDR; NMR; -; A=708-801.
DR   PDB; 3F21; X-ray; 2.20 A; A/B/C=133-209.
DR   PDB; 3F22; X-ray; 2.50 A; A/B/C=133-209.
DR   PDB; 3F23; X-ray; 2.70 A; A/B/C=133-209.
DR   PDB; 3IRQ; X-ray; 2.80 A; A/B/C/D=140-202.
DR   PDB; 3IRR; X-ray; 2.65 A; A/B/C/D=140-202.
DR   PDBsum; 1QBJ; -.
DR   PDBsum; 1QGP; -.
DR   PDBsum; 1XMK; -.
DR   PDBsum; 2ACJ; -.
DR   PDBsum; 2GXB; -.
DR   PDBsum; 2L54; -.
DR   PDBsum; 2MDR; -.
DR   PDBsum; 3F21; -.
DR   PDBsum; 3F22; -.
DR   PDBsum; 3F23; -.
DR   PDBsum; 3IRQ; -.
DR   PDBsum; 3IRR; -.
DR   ProteinModelPortal; P55265; -.
DR   SMR; P55265; 134-199, 294-366, 503-572, 614-683, 708-801.
DR   BioGrid; 106617; 36.
DR   DIP; DIP-29310N; -.
DR   IntAct; P55265; 15.
DR   MINT; MINT-4531596; -.
DR   STRING; 9606.ENSP00000357459; -.
DR   PhosphoSite; P55265; -.
DR   BioMuta; ADAR; -.
DR   DMDM; 313104303; -.
DR   MaxQB; P55265; -.
DR   PaxDb; P55265; -.
DR   PRIDE; P55265; -.
DR   DNASU; 103; -.
DR   Ensembl; ENST00000368471; ENSP00000357456; ENSG00000160710. [P55265-5]
DR   Ensembl; ENST00000368474; ENSP00000357459; ENSG00000160710.
DR   GeneID; 103; -.
DR   KEGG; hsa:103; -.
DR   UCSC; uc001ffh.3; human. [P55265-1]
DR   UCSC; uc001ffi.3; human. [P55265-2]
DR   UCSC; uc001ffj.3; human. [P55265-3]
DR   CTD; 103; -.
DR   GeneCards; GC01M154554; -.
DR   HGNC; HGNC:225; ADAR.
DR   HPA; CAB056157; -.
DR   HPA; HPA003890; -.
DR   HPA; HPA051519; -.
DR   MIM; 127400; phenotype.
DR   MIM; 146920; gene.
DR   MIM; 615010; phenotype.
DR   neXtProt; NX_P55265; -.
DR   Orphanet; 51; Aicardi-Goutieres syndrome.
DR   Orphanet; 41; Dyschromatosis symmetrica hereditaria.
DR   Orphanet; 225154; Familial infantile bilateral striatal necrosis.
DR   PharmGKB; PA24555; -.
DR   eggNOG; NOG292433; -.
DR   GeneTree; ENSGT00550000074412; -.
DR   HOVERGEN; HBG067087; -.
DR   InParanoid; P55265; -.
DR   KO; K12968; -.
DR   OMA; DPKFQYC; -.
DR   OrthoDB; EOG7VHSX4; -.
DR   PhylomeDB; P55265; -.
DR   TreeFam; TF315806; -.
DR   BRENDA; 3.5.4.37; 2681.
DR   Reactome; REACT_1231; C6 deamination of adenosine.
DR   Reactome; REACT_1966; Formation of editosomes by ADAR proteins.
DR   Reactome; REACT_25162; Interferon alpha/beta signaling.
DR   ChiTaRS; ADAR; human.
DR   EvolutionaryTrace; P55265; -.
DR   GeneWiki; ADAR; -.
DR   GenomeRNAi; 103; -.
DR   NextBio; 389; -.
DR   PMAP-CutDB; P55265; -.
DR   PRO; PR:P55265; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P55265; -.
DR   CleanEx; HS_ADAR; -.
DR   ExpressionAtlas; P55265; baseline and differential.
DR   Genevisible; P55265; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0044530; C:supraspliceosomal complex; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003726; F:double-stranded RNA adenosine deaminase activity; NAS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0006382; P:adenosine to inosine editing; IDA:UniProtKB.
DR   GO; GO:0016553; P:base conversion or substitution editing; IDA:MGI.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0060216; P:definitive hemopoiesis; IEA:Ensembl.
DR   GO; GO:0030218; P:erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0061484; P:hematopoietic stem cell homeostasis; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:UniProtKB.
DR   GO; GO:0035280; P:miRNA loading onto RISC involved in gene silencing by miRNA; IDA:MGI.
DR   GO; GO:0016556; P:mRNA modification; TAS:Reactome.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0044387; P:negative regulation of protein kinase activity by regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:1900369; P:negative regulation of RNA interference; IEA:Ensembl.
DR   GO; GO:0060339; P:negative regulation of type I interferon-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IDA:UniProtKB.
DR   GO; GO:0031054; P:pre-miRNA processing; IDA:MGI.
DR   GO; GO:0006611; P:protein export from nucleus; IDA:UniProtKB.
DR   GO; GO:0006606; P:protein import into nucleus; IDA:UniProtKB.
DR   GO; GO:0035455; P:response to interferon-alpha; IDA:UniProtKB.
DR   GO; GO:0009615; P:response to virus; IMP:UniProtKB.
DR   GO; GO:0002566; P:somatic diversification of immune receptors via somatic mutation; IEA:Ensembl.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   Gene3D; 1.10.10.10; -; 2.
DR   Gene3D; 3.30.160.20; -; 3.
DR   InterPro; IPR002466; A_deamin.
DR   InterPro; IPR014720; dsRNA-bd_dom.
DR   InterPro; IPR000607; dsRNA_A_deaminase.
DR   InterPro; IPR011991; WHTH_DNA-bd_dom.
DR   Pfam; PF02137; A_deamin; 1.
DR   Pfam; PF00035; dsrm; 3.
DR   Pfam; PF02295; z-alpha; 2.
DR   SMART; SM00552; ADEAMc; 1.
DR   SMART; SM00358; DSRM; 3.
DR   SMART; SM00550; Zalpha; 2.
DR   PROSITE; PS50141; A_DEAMIN_EDITASE; 1.
DR   PROSITE; PS50139; DRADA_REPEAT; 2.
DR   PROSITE; PS50137; DS_RBD; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Aicardi-Goutieres syndrome; Alternative promoter usage;
KW   Alternative splicing; Antiviral defense; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; DNA-binding; Hydrolase;
KW   Immunity; Innate immunity; Isopeptide bond; Metal-binding;
KW   mRNA processing; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; RNA-binding; RNA-mediated gene silencing;
KW   Ubl conjugation; Zinc.
FT   CHAIN         1   1226       Double-stranded RNA-specific adenosine
FT                                deaminase.
FT                                /FTId=PRO_0000171774.
FT   REPEAT      133    202       DRADA 1.
FT   REPEAT      293    360       DRADA 2.
FT   DOMAIN      503    571       DRBM 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00266}.
FT   DOMAIN      614    682       DRBM 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00266}.
FT   DOMAIN      726    794       DRBM 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00266}.
FT   DOMAIN      886   1221       A to I editase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00240}.
FT   DNA_BIND    169    195
FT   ACT_SITE    912    912       Proton donor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00240}.
FT   METAL       910    910       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00240}.
FT   METAL       966    966       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00240}.
FT   METAL      1036   1036       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00240}.
FT   MOD_RES     601    601       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332}.
FT   MOD_RES     614    614       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   MOD_RES     808    808       Phosphothreonine.
FT                                {ECO:0000269|PubMed:16964243,
FT                                ECO:0000269|PubMed:17924679,
FT                                ECO:0000269|PubMed:18220336,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES     823    823       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   MOD_RES     825    825       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:21406692}.
FT   CROSSLNK    418    418       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   VAR_SEQ       1    295       Missing (in isoform 5).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_019235.
FT   VAR_SEQ       1      5       MNPRQ -> MMSPICDQTIDSRLKVEKATWWGRVGGGSRPH
FT                                WQPPGVRPCPEEVQDP (in isoform 4).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_008872.
FT   VAR_SEQ     694    712       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_008873.
FT   VAR_SEQ     807    832       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_008874.
FT   VARIANT     100    100       R -> G (in dbSNP:rs1466731).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|PubMed:7565688,
FT                                ECO:0000269|PubMed:7972084,
FT                                ECO:0000269|PubMed:9020165,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_048725.
FT   VARIANT     193    193       P -> A (in AGS6).
FT                                {ECO:0000269|PubMed:23001123}.
FT                                /FTId=VAR_069535.
FT   VARIANT     384    384       K -> R (in dbSNP:rs2229857).
FT                                {ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|PubMed:7565688,
FT                                ECO:0000269|PubMed:9020165,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_017240.
FT   VARIANT     587    587       Y -> C (in dbSNP:rs17843865).
FT                                /FTId=VAR_024407.
FT   VARIANT     806    806       E -> V (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035805.
FT   VARIANT     870    870       A -> T (in AGS6).
FT                                {ECO:0000269|PubMed:23001123}.
FT                                /FTId=VAR_069536.
FT   VARIANT     872    872       I -> T (in AGS6).
FT                                {ECO:0000269|PubMed:23001123}.
FT                                /FTId=VAR_069537.
FT   VARIANT     892    892       R -> H (in AGS6).
FT                                {ECO:0000269|PubMed:23001123}.
FT                                /FTId=VAR_069538.
FT   VARIANT     923    923       L -> P (in DSH; dbSNP:rs28936680).
FT                                {ECO:0000269|PubMed:12916015}.
FT                                /FTId=VAR_017604.
FT   VARIANT     966    966       C -> F (in DSH).
FT                                {ECO:0000269|PubMed:15146470}.
FT                                /FTId=VAR_021729.
FT   VARIANT     999    999       K -> N (in AGS6).
FT                                {ECO:0000269|PubMed:23001123}.
FT                                /FTId=VAR_069539.
FT   VARIANT    1007   1007       G -> R (in AGS6).
FT                                {ECO:0000269|PubMed:23001123}.
FT                                /FTId=VAR_069540.
FT   VARIANT    1112   1112       Y -> F (in AGS6).
FT                                {ECO:0000269|PubMed:23001123}.
FT                                /FTId=VAR_069541.
FT   VARIANT    1113   1113       D -> H (in AGS6).
FT                                {ECO:0000269|PubMed:23001123}.
FT                                /FTId=VAR_069542.
FT   VARIANT    1155   1155       R -> W (in DSH).
FT                                {ECO:0000269|PubMed:15659327}.
FT                                /FTId=VAR_026669.
FT   VARIANT    1165   1165       F -> S (in DSH; dbSNP:rs28936681).
FT                                {ECO:0000269|PubMed:12916015}.
FT                                /FTId=VAR_017605.
FT   MUTAGEN     418    418       K->R: Abolishes sumoylation.
FT                                {ECO:0000269|PubMed:16120648}.
FT   CONFLICT     53     53       E -> G (in Ref. 4; CAA55968).
FT                                {ECO:0000305}.
FT   CONFLICT    245    245       F -> L (in Ref. 5; CAE45853).
FT                                {ECO:0000305}.
FT   CONFLICT    482    482       F -> L (in Ref. 5; CAE45853).
FT                                {ECO:0000305}.
FT   CONFLICT    873    873       I -> V (in Ref. 5; CAE45853).
FT                                {ECO:0000305}.
FT   CONFLICT   1093   1093       D -> G (in Ref. 5; CAE45853).
FT                                {ECO:0000305}.
FT   CONFLICT   1184   1184       E -> K (in Ref. 4; CAA55967/CAA55968/
FT                                CAA67169/CAA67170). {ECO:0000305}.
FT   HELIX       127    130       {ECO:0000244|PDB:1QGP}.
FT   HELIX       135    150       {ECO:0000244|PDB:1QBJ}.
FT   STRAND      152    154       {ECO:0000244|PDB:1QGP}.
FT   HELIX       158    165       {ECO:0000244|PDB:1QBJ}.
FT   HELIX       169    181       {ECO:0000244|PDB:1QBJ}.
FT   STRAND      184    192       {ECO:0000244|PDB:1QBJ}.
FT   STRAND      194    197       {ECO:0000244|PDB:1QBJ}.
FT   HELIX       294    309       {ECO:0000244|PDB:1XMK}.
FT   HELIX       315    322       {ECO:0000244|PDB:1XMK}.
FT   HELIX       324    326       {ECO:0000244|PDB:1XMK}.
FT   HELIX       327    339       {ECO:0000244|PDB:1XMK}.
FT   STRAND      342    346       {ECO:0000244|PDB:1XMK}.
FT   STRAND      348    350       {ECO:0000244|PDB:1XMK}.
FT   STRAND      352    355       {ECO:0000244|PDB:1XMK}.
FT   HELIX       357    360       {ECO:0000244|PDB:1XMK}.
FT   TURN        361    363       {ECO:0000244|PDB:1XMK}.
FT   HELIX       716    724       {ECO:0000244|PDB:2MDR}.
FT   HELIX       727    738       {ECO:0000244|PDB:2MDR}.
FT   STRAND      742    749       {ECO:0000244|PDB:2MDR}.
FT   STRAND      758    764       {ECO:0000244|PDB:2MDR}.
FT   STRAND      767    776       {ECO:0000244|PDB:2MDR}.
FT   HELIX       777    796       {ECO:0000244|PDB:2MDR}.
SQ   SEQUENCE   1226 AA;  136066 MW;  9CE095D6F9C1BC79 CRC64;
     MNPRQGYSLS GYYTHPFQGY EHRQLRYQQP GPGSSPSSFL LKQIEFLKGQ LPEAPVIGKQ
     TPSLPPSLPG LRPRFPVLLA SSTRGRQVDI RGVPRGVHLR SQGLQRGFQH PSPRGRSLPQ
     RGVDCLSSHF QELSIYQDQE QRILKFLEEL GEGKATTAHD LSGKLGTPKK EINRVLYSLA
     KKGKLQKEAG TPPLWKIAVS TQAWNQHSGV VRPDGHSQGA PNSDPSLEPE DRNSTSVSED
     LLEPFIAVSA QAWNQHSGVV RPDSHSQGSP NSDPGLEPED SNSTSALEDP LEFLDMAEIK
     EKICDYLFNV SDSSALNLAK NIGLTKARDI NAVLIDMERQ GDVYRQGTTP PIWHLTDKKR
     ERMQIKRNTN SVPETAPAAI PETKRNAEFL TCNIPTSNAS NNMVTTEKVE NGQEPVIKLE
     NRQEARPEPA RLKPPVHYNG PSKAGYVDFE NGQWATDDIP DDLNSIRAAP GEFRAIMEMP
     SFYSHGLPRC SPYKKLTECQ LKNPISGLLE YAQFASQTCE FNMIEQSGPP HEPRFKFQVV
     INGREFPPAE AGSKKVAKQD AAMKAMTILL EEAKAKDSGK SEESSHYSTE KESEKTAESQ
     TPTPSATSFF SGKSPVTTLL ECMHKLGNSC EFRLLSKEGP AHEPKFQYCV AVGAQTFPSV
     SAPSKKVAKQ MAAEEAMKAL HGEATNSMAS DNQPEGMISE SLDNLESMMP NKVRKIGELV
     RYLNTNPVGG LLEYARSHGF AAEFKLVDQS GPPHEPKFVY QAKVGGRWFP AVCAHSKKQG
     KQEAADAALR VLIGENEKAE RMGFTEVTPV TGASLRRTML LLSRSPEAQP KTLPLTGSTF
     HDQIAMLSHR CFNTLTNSFQ PSLLGRKILA AIIMKKDSED MGVVVSLGTG NRCVKGDSLS
     LKGETVNDCH AEIISRRGFI RFLYSELMKY NSQTAKDSIF EPAKGGEKLQ IKKTVSFHLY
     ISTAPCGDGA LFDKSCSDRA MESTESRHYP VFENPKQGKL RTKVENGEGT IPVESSDIVP
     TWDGIRLGER LRTMSCSDKI LRWNVLGLQG ALLTHFLQPI YLKSVTLGYL FSQGHLTRAI
     CCRVTRDGSA FEDGLRHPFI VNHPKVGRVS IYDSKRQSGK TKETSVNWCL ADGYDLEILD
     GTRGTVDGPR NELSRVSKKN IFLLFKKLCS FRYRRDLLRL SYGEAKKAAR DYETAKNYFK
     KGLKDMGYGN WISKPQEEKN FYLCPV
//
